Erasca, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ERAS research report →
About the company
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors.
- CEO
- Jonathan E. Lim
- IPO
- 2021
- Employees
- 103
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $5.74B
- P/E
- -19.86
- P/S
- 0.00
- P/B
- 14.28
- EV/EBITDA
- -21.21
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -77.01%
- ROIC
- -32.56%
- Revenue
- $0 · 0.00%
- Net Income
- $-124,546,000 · 22.95%
- EPS
- $-0.44 · 36.23%
- Op Income
- $-131,405,000
- FCF YoY
- 27.58%
- 52W High
- $24.28
- 52W Low
- $1.33
- 50D MA
- $13.39
- 200D MA
- $9.22
- Beta
- 0.67
- Avg Volume
- 6.96M
Get TickerSpark's AI analysis on ERAS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 26, 26 | Start Valerie Denise Harding | other | 29,888 |
| Jun 26, 26 | LIU JEAN I | other | 29,888 |
| Jun 26, 26 | Multani Pratik S | other | 29,888 |
| Jun 26, 26 | Casdin Alexander W. | other | 29,888 |
| Jun 26, 26 | Hambleton Julie | other | 29,888 |
| Jun 26, 26 | Bristol James Arthur | other | 29,888 |
| Apr 1, 26 | Garner Ebun | other | 80,000 |
| Apr 1, 26 | Garner Ebun | other | 80,000 |
| Apr 1, 26 | Garner Ebun | sell | 80,000 |
| Mar 4, 25 | Morris Shannon | other | 20,000 |
Our ERAS coverage
Recent articles, reports, and earnings notes.
No research on ERAS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ERAS report →Similar companies
Peers in the same neighborhood.